Author

D. R. Weilhammer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

A. M. Phillips· 2 shared E. A. Saada· 2 shared F. A. Bourguet· 2 shared A. Ladd· 1 shared A. M. Lillo· 1 shared A. Rasley· 1 shared A. Sebastian· 1 shared A. T. Zemla· 1 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. M. Phillips

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants

T. A. Desautels, K. T. Arrildt, A. T. Zemla, E. Y. Lau, F. Zhu, D. Ricci, S. Cronin, S. Zost, E. Binshtein, S. M. Scheaffer, B. Dadonaite, B. K. Petersen, T. B. Engdahl, E. Chen, L. S. Handal, , Carnahan

This paper computationally redesigns an antibody to restore potency against SARS-CoV-2 Omicron subvariants while maintaining efficacy against Delta and other variants.

Nature · May 8, 2024Peer-reviewedMicrobiology

MAVS mediates a protective immune response in the brain to Rift Valley fever virus

D. R. Weilhammer, N. R. Hum, F. A. Bourguet, A. Sebastian, D. Lam, A. M. Phillips, K. R. Sanchez, A. Rasley, G. G. Loots

This study shows that MAVS is critical for microglial antiviral responses in the brain during RVFV infection, reducing viral burden and mortality.

bioRxiv · Dec 22, 2021Immunology

Development of Potent and Effective Synthetic SARS-CoV-2 Neutralizing Nanobodies

M. A. Stefan, Y. K. Light, J. L. Schwedler, P. R. McIlroy, C. M. Courtney, E. A. Saada, C. E. Thatcher, A. M. Phillips, F. A. Bourguet, C. M. Mageeney, S. A. McCloy, N. M. Collette, O. A. Negrete, J. S. Schoeniger, D. R. Weilhammer, B. Harmon

This paper identifies and characterizes potent SARS-CoV-2 neutralizing nanobodies that block viral entry and show efficacy in vivo.

mAbs · Aug 4, 2021Peer-reviewedImmunology